An FDA advisory panel voted this week to add six peptides to the drug compounding list, including compounds like kisspeptin-10 and TB-500. The panel rejected emideltide. HIMS stock rose as shares jumped overnight after the committee backed four peptides. Bachem shares held steady after the vote. A recent study indicated peptides may help treat antibiotic-resistant bacteria. Meanwhile, Robert F. Kennedy Jr. pushed for easier access to controversial peptides, calling for reduced restrictions. The vote reflects a broader shift in how policymakers view specialty peptide therapies, which have drawn growing interest from patients seeking alternatives to conventional drugs. Researchers say peptide treatments could alter approaches to resistant infections, though concerns about quality persist. The committee's endorsement of six peptides opens the door for more widespread prescribing, even as critics warn of short-term evidence. Sector observers note that peptide-focused companies may see increased investor attention following the panel's decision. The rejection of emideltide, meanwhile, highlights the FDA's cautious stance on particular peptide candidates.